- Home
- FSP vs GNLX Comparison
FSP vs GNLX Comparison
Compare FSP & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSP
- GNLX
- Stock Information
- Founded
- FSP 1981
- GNLX 2001
- Country
- FSP United States
- GNLX United States
- Employees
- FSP N/A
- GNLX N/A
- Industry
- FSP Real Estate Investment Trusts
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- FSP Real Estate
- GNLX Health Care
- Exchange
- FSP Nasdaq
- GNLX Nasdaq
- Market Cap
- FSP 159.5M
- GNLX 184.4M
- IPO Year
- FSP N/A
- GNLX 2023
- Fundamental
- Price
- FSP $1.52
- GNLX $2.63
- Analyst Decision
- FSP
- GNLX Strong Buy
- Analyst Count
- FSP 0
- GNLX 4
- Target Price
- FSP N/A
- GNLX $18.25
- AVG Volume (30 Days)
- FSP 424.6K
- GNLX 233.3K
- Earning Date
- FSP 04-29-2025
- GNLX 05-08-2025
- Dividend Yield
- FSP 2.61%
- GNLX N/A
- EPS Growth
- FSP N/A
- GNLX N/A
- EPS
- FSP N/A
- GNLX N/A
- Revenue
- FSP $120,112,000.00
- GNLX $8,000.00
- Revenue This Year
- FSP $4.36
- GNLX N/A
- Revenue Next Year
- FSP $0.81
- GNLX N/A
- P/E Ratio
- FSP N/A
- GNLX N/A
- Revenue Growth
- FSP N/A
- GNLX N/A
- 52 Week Low
- FSP $1.36
- GNLX $1.60
- 52 Week High
- FSP $2.21
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- FSP 32.73
- GNLX 42.31
- Support Level
- FSP $1.36
- GNLX $2.30
- Resistance Level
- FSP $1.84
- GNLX $2.68
- Average True Range (ATR)
- FSP 0.09
- GNLX 0.26
- MACD
- FSP -0.02
- GNLX 0.05
- Stochastic Oscillator
- FSP 33.33
- GNLX 55.49
About FSP Franklin Street Properties Corp.
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The company's operations include rental income from real estate leasing, interest income from secured loans made on office properties, property dispositions, and fee income from asset/property management and development. Franklin Street markets Atlanta, Dallas, Denver, Houston, and Minneapolis.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.